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Abstract
Background: Donor site wounds after split-skin grafting are rather ‘standard’ wounds. At present, lots of dressings
and topical agents for donor site wounds are commercially available. This causes large variation in the local care of
these wounds, while the optimum ‘standard’ dressing for local wound care is unclear. This protocol describes a trial
in which we investigate the effectiveness of various treatment options for these donor site wounds.
Methods: A 14-center, six-armed randomized clinical trial is being carried out in the Netherlands. An a-priori power
analysis and an anticipated dropout rate of 15% indicates that 50 patients per group are necessary, totaling 300
patients, to be able to detect a 25% quicker mean time to complete wound healing. Randomization has been
computerized to ensure allocation concealment. Adult patients who need a split-skin grafting operation for any
reason, leaving a donor site wound of at least 10 cm
2 are included and receive one of the following dressings:
hydrocolloid, alginate, film, hydrofiber, silicone dressing, or paraffin gauze. No combinations of products from other
intervention groups in this trial are allowed. Optimum application and changes of these dressings are pursued
according to the protocol as supplied by the dressing manufacturers. Primary outcomes are days to complete
wound healing and pain (using a Visual Analogue Scale). Secondary outcomes are adverse effects, scarring, patient
satisfaction, and costs. Outcome assessors unaware of the treatment allocation will assess whether or not an
outcome has occurred. Results will be analyzed according to the intention to treat principle. The first patient was
randomized October 1, 2009.
Discussion: This study will provide comprehensive data on the effectiveness of different treatment options for donor
site wounds. The dressing(s) that will prevail in effectiveness, satisfaction and costs will be promoted among clinicians
dealing with such patients. Thus, we aim to contribute a well-designed trial, relevant to all clinicians involved in the care
for donor site wounds, which will help enhance uniformity and quality of care for these patients.
Trial registration: http://www.trialregister.nl, NTR1849. Date registered: June 9, 2009
Background
Split skin grafting (SSG) is a widely used reconstructive
technique to repair skin defects (e.g. burns, chronic, and
traumatic wounds) [1,2], including those that cannot be
covered by a skin flap or are not likely to heal by second-
ary intention [3]. The wound created after harvesting the
skin is called the donor site wound (DSW). Depending on
the thickness of the SSG, the DSW should re-epithelialize
completely in 7 to 21 days [3]. Optimum local care for
these DSWs should promote wound healing and be cost-
effective, while it should prevent complications, such as
pain, discomfort, infection, and scarring. Particularly pain
and discomfort are reported to occur more frequently
from DSWs than at the recipient site [3-5].
Clinical practice shows a large number of dressings and
topical agents for DSWs, while the optimum dressing
choice for local wound care is unclear [1,2,6,7]. Conse-
quently, large variation exists among health care profes-
sionals regarding their choice for wound dressing
materials or topical agents to treat DSWs [8-10]. Based
on national surveys, alginates appear to be the most com-
monly used primary dressing [8-10], probably due to
their additional haemostatic properties [11,12]. They are
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paraffin gauzes [8].
Available evidence comprises four systematic reviews
(SRs), presenting a lack of strong evidence for the effective-
ness of the different dressings for the treatment of DSWs,
especially for alginates [1,2,6,7]. These SRs tentatively con-
clude that moist dressings are preferable over non-moist
dressings in terms of wound healing. Hydrocolloid and
films seem better than nearly all other materials (e.g. algi-
nates, paraffin gauzes, hydrofibers, and foams) as to healing
and pain [7]. Hydrofibers in turn seem to outperform tulle
dressings in terms of wound healing and pain [13,14].
Although tulle dressings seem to be least suitable for the
local treatment of DSWs, recent evidence shows that
gauze-based dressings still have a place in wound care [15].
Some centers still adhere, or have returned to, these gauze-
based dressings [16]. Silicone-based dressings have the
advantage of being non-adhesive, although they tend to
dislocate easily and do not seem to outperform alginates
[17]. These conclusions are formulated cautiously as most
authors state that more well designed and rigorous studies
are needed.
We therefore conceived a trial to compare the six most
promising dressing groups, based on common usage and
available evidence. In this paper we will report on the
design of our 14-center six-armed randomized clinical
trial (RCT). This trial received the acronym “Rembrandt”
trial, which stands for Recognizing Effective Materials By
Randomizing & Assessing New Donorsite Treatments. In
this trial we aim to answer the following question: Which
of the following dressing materials for DSW of SSGs stand
out in effectiveness: hydrocolloids, alginates, films, hydrofi-
bers, silicone dressings, or paraffin gauzes, in terms of
wound healing, adverse effects (e.g. pain and scarring), and
costs?
Methods
Protocol and registration
The methods applied in our 14-center RCT were specified
in advance, documented in a protocol, and registered
(http://www.trialregister.nl, NTR 1849). The study was
approved by the local medical ethics committee and by
the institutional review boards of each participating hospi-
tal or burns centre. The methods used are summarized
here according to the revised CONSORT Statement [18].
Design and setting
We designed a national, 14-center RCT with six treat-
ment groups in the Netherlands (Figure 1). The coordi-
nating center (Academic Medical Center at the
University of Amsterdam) invited hospitals (i.e. depart-
ments of surgery, plastic surgery and otorhinolaryngol-
ogy) and burns centers to participate in the trial,
resulting in 13 contributing hospitals (4 university
hospitals, 5 teaching clinics and 4 general hospitals) and
1 burns center.
Eligibility criteria for patients
In this trial we include all adult patients, either hospita-
lized or under treatment in the outpatient clinic in one of
the contributing hospitals or burns centre, who need a
SSG-operation for any reason. The DSW should have a
minimum size of 10 cm
2 (to allow proper application and
investigation of the study dressings) and be suitable for all
treatment options in the trial. Patients are included after
full, understandable and neutral explanation by the treat-
ing physician or coordinating investigators and after giving
written informed consent. Patients are excluded when
they receive a treatment known to seriously impair normal
wound healing (e.g. chemotherapy, corticosteroids, or
local irradiation therapy) or if patients are not physically
or mentally able to consent.
Interventions
Before starting the trial, manufactures of the products
involved were invited to develop a protocol how best to
apply their wound materials for DSWs, to ensure correct
and uniform application of the six different dressing
groups:
1. A paraffin gauze-based material (e.g. Jelonet
®,
Adaptic
®);
2. A hydrocolloid (e.g. DuoDERM
® E);
3. An alginate (e.g. Kaltostat
®, Algisite
®,
Melgisorb
®);
4. A semi-permeable film (e.g. Tegaderm
®, Opsite
®);
5. A silicone dressing (e.g. Mepitel
®);
6. A hydrofiber (e.g. Aquacel
®).
The coordinating investigators (FEB and AME) or dres-
sing manufactures orally instructed medical and nursing
staff on the wards and out-patient clinics of the contribut-
ing centers at the beginning of the trial. Furthermore, they
received written application advices as reminders for a
uniform treatment protocol, e.g. regarding change fre-
quency and treatment duration. Posters and pocket charts
were also distributed to inform about inclusion criteria
and contact persons.
Surgical procedure
A SSG operation is to be performed with an electric or
pneumatic dermatome or free hand-knife, according to
local best practice. The SSG should preferably be between
0.20 and 0.30 mm to achieve a reasonably uniform depth
of the DSW and should be taken from thighs, arms or but-
tocks. Method of hemostasis of the DSW is at the discre-
tion of the surgeon (e.g. adrenaline-soaked gauze).
However, the decision to use hemostasis must be made
before randomization and will be recorded.
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Local wound care according to the assigned dressing
group starts directly after randomization (see head-
ing Randomization). The brand of the dressing will be
recorded. No combinations of products from other dres-
sing groups in this trial are allowed to ensure that the effect
found after completion of the trial can be attributed only to
the dressing to which the patient was allocated. The opti-
mum changing frequency will be pursued as advised for
each dressing material. This may differ from no dressing
changes (e.g. hydrofiber) to daily changes in case of leakage
(e.g. hydrocolloid or paraffin gauze). We allow coverage of
the primary dressings with cotton gauzes and bandages.
The type of secondary dressings used will be recorded.
Furthermore, we will record any crossovers and make sure
the patient returns to the initially allotted dressing.
Co-interventions
Additional wound debridement, cleansing or protection
may be indicated during a dressing change and is allowed
in all treatment arms, as this reflects real life. In case of
an (impending) wound infection, the wound may be
treated with iodine (Povidone- or Cadexomer iodine), to
be applied beneath the allotted dressing material [19].
The type of iodine used will be recorded.
Study outcomes
Primary endpoints
The primary endpoint with respect to the effectiveness of
wound dressings in the treatment of DSWs is time to
complete wound healing. We define wound healing as re-
epithelialization of the total wound surface. We decided
this is not the case until all crusts have come off. This end-
point is to be assessed by an independent investigator who
is not aware of the treatment given. The second primary
outcome is pain from the donor site area. It is documen-
ted by the patient on a Visual Analogue Scale (VAS), vary-
ing from 0 (no pain) to 10 (intolerable pain). This is
scored daily for the first two weeks postoperatively and
twice a week during the third and fourth week, in a
patient-held diary. Both primary endpoints are meaningful
and relevant to patients and were therefore used for the
sample size calculation [20].
Recruitment:
300 patients in 14 medical centers
Randomisation
Doctors or specialized wound care nurses 
explain aim and procedures of study
Baseline assessment and evaluation of 
eligibility criteria
entan
Written informed consent from patients
i
Hydrocolloid Paraffin gauze Alginate Film Silicone Hydrofiber
Start
October 2009
Measuring outcomes
Follow-up completed 
3 months after complete
wound healing
Figure 1 Flowchart of the Rembrandt Trial.
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As secondary endpoints we assess the occurrence of local
complications, e.g. wound infections, based on clinical
symptoms of infection, scarring at 12 weeks postoperatively
(using Patient and Observer Scar Assessment Scale
(POSAS) assessed by the patients themselves and research-
ers, treating physicians or specialized wound nurses) [21],
patient satisfaction (varying from 1 (absolutely dissatisfied)
to 10 (absolutely satisfied), and costs (material and nursing
costs). Itching scores are also collected by using a VAS,
ranging from 0 (no itching) to 10 (intolerable itching) and
obtained through the patient-held diary.
Randomization
Patients are to be randomized in the operation theatre,
just after the skin harvest and hemostasis, and before the
DSW is to be dressed. In each contributing center an
appointed officer performs the randomization using an
online computer software program (ALEA NKI-AVL,
Amsterdam, The Netherlands, Release: 2.2.) to ensure
allocation concealment. The trial is stratified by center,
with a balanced allocation ratio for each treatment arm
using a biased coin [22]. The biased coin method pre-
serves most of the unpredictability associated with simple
randomization [22].
Blinding
Blinding of patients and care-providers (e.g. doctors and
nurses) is not possible because the treatment options can-
not be masked. To overcome this possible source of perfor-
mance bias, independent doctors and nurses of the
outpatient clinic, who are unaware of the treatment alloca-
tion, will assess whether or not an endpoint has occurred
[23].
Sample size
The study size calculation (using nQuery Advisor version
7.0, Statistical Solutions Ltd, Cork, Ireland) was based on
two primary outcomes using a one-way analysis of variance.
To detect a 25% quicker mean wound healing, which is in
agreement with the study of Wiechula [2], and with a 5%
significance level, a power of 90%, and a standard deviation
(SD) of 3 days, a sample size of 50 patients per group is
necessary, given an anticipated dropout rate of 15%. This
number also allows detection of a minimum difference in
pain scores of 2.0 or greater (with a SD of 2) on the VAS
and discernment of a cost difference of €2p e rd a y .T o
recruit this number of patients an 18-month inclusion per-
iod is anticipated based on the performed number of SSGs
as estimated by each of the 14 co-operating hospitals.
Data collection
The coordination center designed a standardized case
record form (CRF) and distributes this in a paper-based
or electronic version. The latter one is made available
through a secured website, http://www.rembrandt-trial.
nl (using Joomla, an open-source website software pack-
age), which also facilitates remote patient randomization
and data entry. We collect copies of all completed forms
from the co-operating hospitals and maintain the data-
base using SPSS software (PASW statistics version 18.0,
IBM, Armonk, NY, USA). Data are collected on baseline
demographic and clinical patient characteristics of each
group, whether the patients receive the allotted treat-
ment and complete the study protocol, and are analyzed
for the primary outcomes. Patients whose treatment
deviates from the initial allocation will be described
together with the reasons for this. Data on all important
adverse events or side effects in each intervention group
are recorded as well. Data from the patient-held diaries
will be returned to the coordinating center. Double data
entry will be conducted by FEB and AME, and com-
pared using the SPSS Data Entry Builder program
(Release 4.0.2). We will resolve any discrepancies by dis-
cussion and by re-checking the data.
Data monitoring
Data completeness is reviewed weekly, and reminders or
queries are sent timely. FEB and AME visit the cooperat-
ing hospitals on a regular basis to promote the trial and to
be closely associated with the data collection. Thus, an
accurate and complete data set is ensured. Because no
(serious) adverse effects were expected from the commer-
cially available dressings that would require interim analy-
sis, we refrained from installing a data safety monitoring
board.
Data analysis
Data coding and analysis will be carried out using SPSS
software (PASW statistics version 18.0, IBM, Armonk, NY,
USA). Differences in outcome variables will be analyzed
on an intention-to-treat basis. A general linear model will
be used to analyze the differences between the treatment
arms for the various endpoints measured repeatedly, as
the data are likely to be unequally distributed. Differences
in wound healing time between the dressing groups will
be examined using the Kaplan-Meier method and the
Mantel-Cox log-rank test. Data analysis will be conducted
by the authors and replicated by the Clinical Research
Unit of the coordinating hospital. We will record any
crossovers and make sure the patient returns to the initi-
ally allotted dressing. Missing data are dealt with by using
the Generalized Estimating Equations model in our statis-
tical analysis.
Data storage
Data are stored at the coordinating center in a Trial
Master File and at the co-operating hospital sites, where
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will be saved for at least 5 years, in accordance with the
r e c o m m e n d a t i o n sa st ol o wr i s ks t u d i e so ft h eD u t c h
Federation of University Medical Centers.
Discussion
In current clinical practice, a ‘standard’ wound such as a
DSW does not appear to be associated with a uniform
dressing choice [8]. Also the systematic reviews of avail-
able literature report a large clinical heterogeneity among
the available trials [1,2,6,7]. To date, available evidence
allows the tentative conclusion that dressings creating a
moist environment seem to be preferable over gauze-
based dressings in the management of DSWs. This
recommendation is tentatively formulated because strong
recommendations for clinical practice are hard to draw,
mainly due to the poor quality and small sample sizes of
the available trials. Therefore, most systematic reviews
recommend new and large randomized clinical trials
[2,6,7].
However, doing research in the realm of wound care
involves much more than simply comparing wound care
products in eligible patients. It poses many methodolo-
gical and practical challenges in the design and execu-
tion of trials [24].
The first challenge is the design of our, intentionally
pragmatic, RCT. To enhance the applicability and gener-
alizability of the results of this trial, we chose a multicen-
ter trial design and recruited patients from low- and
high-volume centers like teaching hospitals and burns
centers. We realize that for many surgical procedures,
patients have better outcomes in high-volume centers
[25-29]. However, split-skin grafting is a rather common
procedure, also in smaller hospitals. Second, we are for-
bearing regarding local clinical care, for example by
allowing several brands within each dressing group, dif-
ferent depths of skin grafting, and different methods of
hemostasis. This helps mimicking ‘real life’, at the cost of
losing some contrast between the six treatment arms.
Although we are liberal and pragmatic at some points,
we feel we need to and can be strict in others. We urge
the contributing centers to adhere to the same dressing
type until complete wound healing is reached. This allows
us to appreciate the true effects of each of the dressing
types studied. Some argue this is not reflecting common
practice [30], in which the dressing type is changed in
response to any change in the clinical condition of the
wound during the healing process. We do not think this
will be a frequently occurring issue since these superficial
DSWs usually have fairly short healing times. The protocol
does allow for an antiseptic agent to be added in case of an
(impending) wound infection.
Another frequent methodological challenge in wound
care research is the use of subjective or surrogate
outcome variables. In this trial we aim to measure our
endpoints in a reliable and valid way. We strictly prede-
fined our primary endpoint, time to complete wound
healing. In a previous study it was shown that, by using
this strict definition, specialized nurses had a better
inter-observer agreement than doctors or nurses regard-
ing the assessment of complete wound healing [31].
Therefore, in this trial predominantly specialized nurses
will assess our primary endpoint. Our second primary
outcome variable, pain, is measured using VAS scores.
This is a reliable and acknowledged scale for general clin-
ical use [32,33].
Today, financial support is a necessity to properly con-
duct a (multicenter) trial. For this purpose, we obtained
funding from an independent institution, i.e. the Dutch
Burns Foundation, which is to be preferred over subven-
tion from one or more dressing manufacturers to avoid
any publication bias. To avoida n yc o n f l i c to fi n t e r e s t ,
analysis and reporting of the trial stays the domain of the
investigators.
The strengths of this trial are firstly the fruitful colla-
boration with manufacturers, who developed a dedicated
protocol for the treatment of the DSW with their pro-
duct. This greatly supports the uniform application of
each dressing type under study. Second, using this six-
armed, multicenter trial we investigate the effectiveness
of the dressings most commonly used in the Nether-
lands and most promising from the available literature.
This will facilitate implementation of the results. We
expect to present the results of this trial in the course of
2012.
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